Coya Therapeutics, Common Stock Revenue
| COYA Stock | 6.85 0.36 5.55% |
Coya Therapeutics, Common fundamentals help investors to digest information that contributes to Coya Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Coya Stock. The fundamental analysis module provides a way to measure Coya Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coya Therapeutics, stock.
Coya |
Coya Therapeutics, Common Company Revenue Analysis
Coya Therapeutics,'s Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Coya Therapeutics, Revenue | 6 M |
Most of Coya Therapeutics,'s fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coya Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Coya Therapeutics, Common reported 6 M of revenue. This is 99.92% lower than that of the Biotechnology sector and 99.19% lower than that of the Health Care industry. The revenue for all United States stocks is 99.94% higher than that of the company.
Coya Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coya Therapeutics,'s direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coya Therapeutics, could also be used in its relative valuation, which is a method of valuing Coya Therapeutics, by comparing valuation metrics of similar companies.Coya Therapeutics, is currently under evaluation in revenue category among its peers.
Coya Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.17) % | ||||
| Current Valuation | 122.92 M | ||||
| Shares Outstanding | 16.71 M | ||||
| Shares Owned By Insiders | 7.04 % | ||||
| Shares Owned By Institutions | 26.72 % | ||||
| Number Of Shares Shorted | 259.49 K | ||||
| Price To Book | 3.35 X | ||||
| Price To Sales | 11.35 X | ||||
| Revenue | 6 M | ||||
| Gross Profit | (1.98 M) | ||||
| EBITDA | (7.88 M) | ||||
| Net Income | (7.99 M) | ||||
| Total Debt | 5.63 M | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (11.19 M) | ||||
| Short Ratio | 2.46 X | ||||
| Earnings Per Share | (0.65) X | ||||
| Target Price | 15.5 | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 108.43 M | ||||
| Total Asset | 41.26 M | ||||
| Retained Earnings | (25.86 M) | ||||
| Working Capital | 36.14 M | ||||
| Net Asset | 41.26 M |
About Coya Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coya Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coya Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coya Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:Check out Coya Therapeutics, Piotroski F Score and Coya Therapeutics, Altman Z Score analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.